{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:43:53Z","timestamp":1790009033644,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00592-015-0817-x","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T02:17:40Z","timestamp":1450664260000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study"],"prefix":"10.1007","volume":"53","author":[{"given":"Tsung-Yuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Po","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Rong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwo-Chang","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"issue":"Suppl 1","key":"817_CR1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association (2013) Standards of medical care in diabetes\u20142013. Diabetes Care 36(Suppl 1):S11\u2013S66","journal-title":"Diabetes Care"},{"key":"817_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129\u2013139","journal-title":"N Engl J Med"},{"issue":"24","key":"817_CR3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560\u20132572","journal-title":"N Engl J Med"},{"issue":"9","key":"817_CR4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364(9):818\u2013828","journal-title":"N Engl J Med"},{"issue":"3","key":"817_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng CL, Kao YH, Lin SJ et al (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20(3):236\u2013242","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"817_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or Insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"817_CR7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel A et al (2008) 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589","journal-title":"N Engl J Med"},{"issue":"245","key":"817_CR8","first-page":"77724","volume":"73","author":"Guidance for industry","year":"2008","unstructured":"Guidance for industry (2008) Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes; availability. Food Drug Adm 73(245):77724\u201377725","journal-title":"Food Drug Adm"},{"key":"817_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-12-3","volume":"12","author":"SS Engel","year":"2013","unstructured":"Engel SS, Golm GT, Shapiro D et al (2013) Cardiovascular safety of Sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 12:3","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"817_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.05.2138","volume":"122","author":"R Frederich","year":"2010","unstructured":"Frederich R, Alexander JH, Fiedorek FT et al (2010) A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 122(3):16\u201327","journal-title":"Postgrad Med"},{"key":"817_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Engel S, Round E et al (2010) Safety and tolerability of Sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 10:7","journal-title":"BMC Endocr Disord"},{"issue":"Supplement B","key":"817_CR12","doi-asserted-by":"crossref","first-page":"B22","DOI":"10.1093\/eurheartj\/sus003","volume":"14","author":"O Mosenzon","year":"2012","unstructured":"Mosenzon O, Raz I (2012) Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials. Eur Heart J Suppl 14(Supplement B):B22\u2013B29","journal-title":"Eur Heart J Suppl"},{"key":"817_CR13","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","volume":"346","author":"HR Patil","year":"2013","unstructured":"Patil HR, Al Badarin FJ, Al Shami HA et al (2013) Comparative safety and effectiveness of Sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 346:f2267","journal-title":"BMJ"},{"key":"817_CR14","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","volume":"346","author":"DT Eurich","year":"2013","unstructured":"Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA (2013) Comparative safety and effectiveness of Sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 346:f2267","journal-title":"BMJ"},{"issue":"3","key":"817_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/dom.12197","volume":"16","author":"NM Scheller","year":"2014","unstructured":"Scheller NM, Mogensen UM, Andersson C et al (2014) All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor Sitagliptin compared with metformin, a retrospective cohort study on the Danish population. Diabetes Obes Metab 16(3):231\u2013236","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"817_CR16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2014.12.029","volume":"181","author":"DY Chen","year":"2015","unstructured":"Chen DY, Wang SH, Mao CT et al (2015) Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol 181(15):200\u2013206","journal-title":"Int J Cardiol"},{"issue":"14","key":"817_CR17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317\u20131326","journal-title":"N Engl J Med"},{"issue":"14","key":"817_CR18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327\u20131335","journal-title":"N Engl J Med"},{"key":"817_CR19","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. doi: 10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-015-0817-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-015-0817-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-015-0817-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T15:39:49Z","timestamp":1567438789000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-015-0817-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s00592-015-0817-x","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}